Clinical trial

Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy

NCT05796089

Study summary

ClinicalTrials.gov

Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

RADIATION · Unmapped registry intervention Thoracic Radiotherapy Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Etoposide with Carboplatin or Cisplatin Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Durvalumab Normalized identity: durvalumab View linked drug · Find medicine records · Find other trials using this name

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2022-01-01

PhasePHASE2

Conditions

Extensive-Stage Small-Cell Lung Cancerunresolved

Interventions

Thoracic RadiotherapyRADIATION

Etoposide with Carboplatin or CisplatinDRUG

DurvalumabDRUG · verified · RxNorm: durvalumab

Sponsors & collaborators

Trans Tasman Radiation Oncology Grouplead sponsor

AstraZenecacollaborator

Mapped research locations

MelbourneVictoria, Australia3 SydneyNew South Wales, Australia3 BrisbaneQueensland, Australia2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05796089 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.